Action | DRS | |||
---|---|---|---|---|
HMS_LINCS&file=LDS-1210.tar.gz | Other |
Items per page: 5 1 - 1 of 1 |
Fallahi-Sichani Mohammad M Moerke Nathan J NJ Niepel Mario M Zhang Tinghu T Gray Nathanael S NS Sorger Peter K PK
Molecular systems biology 20150326 3
Drugs that inhibit RAF/MEK signaling, such as vemurafenib, elicit profound but often temporary anti-tumor responses in patients with BRAF(V) (600E) melanoma. Adaptive responses to RAF/MEK inhibition occur on a timescale of hours to days, involve homeostatic responses that reactivate MAP kinase signaling and compensatory mitogenic pathways, and attenuate the anti-tumor effects of RAF/MEK inhibitors. We profile adaptive responses across a panel of melanoma cell lines using multiplex biochemical me ...[more]